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Kidney volume growth is considered the best surrogate
marker predicting the decline of renal function in autosomal
dominant polycystic kidney disease. To assess the
therapeutic benefit of new drugs more rapidly, changes in
kidney volume need to be determined over a short time
interval. Here we measured renal volume changes by manual
segmentation volumetry applied to magnetic resonance
imaging scans obtained with an optimized T1-weighted
acquisition protocol without gadolinium-based contrast
agents. One hundred young patients with autosomal
dominant polycystic kidney disease and preserved renal
function had a significant increase in total kidney volume by
2.71±4.82% in 6 months. Volume measurements were
highly reproducible and accurate, as indicated by correlation
coefficients of 1.000 for intra-observer and 0.996 for inter-
observer agreement, with acceptable within-subject standard
deviations. The change in renal volume correlated with
baseline total kidney volume in all age subgroups. Total
kidney volume positively correlated with male gender,
hypertension, albuminuria and a history of macrohematuria
but negatively with creatinine clearance. Albuminuria was
associated with accelerated volume progression. Our study
shows that increases in kidney volume can be reliably
measured over a 6 month period in early autosomal
dominant polycystic kidney disease using unenhanced
magnetic resonance imaging sequences.
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Autosomal dominant polycystic kidney disease (ADPKD) is
characterized by the development of innumerable cysts that
originate from the tubular epithelium of the nephrons.1 The
disease affects all ethnic groups worldwide with an incidence
of 1:500–1:1000.2 The continuous growth of cysts leads to
progressive kidney enlargement and subsequently to a loss of
renal function.3 Currently, specific treatment for ADPKD
other than supportive care does not exist, but clinical trials
have recently been initiated to examine the efficacy of various
drugs in ADPKD, including the mTOR inhibitors sirolimus
(rapamycin) and everolimus, the vasopressin V2 receptor
antagonist tolvaptan, the somatostatin analogue octreotide-
acetate, and combined therapy with angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers.4,5
In patients with ADPKD, the glomerular filtration rate
remains stable for decades because of compensatory mechan-
isms.6 By the time renal function starts to decline, the kidneys
are usually massively enlarged, and little normal renal
parenchyma is recognizable on imaging studies. Thus, early
intervention in ADPKD promises more therapeutic benefit
than late treatment, as cysts have not yet replaced the bulk of
intact renal parenchyma and renal function is still main-
tained.4,6,7
The analysis of sequential magnetic resonance imaging
(MRI) or computed tomography scans can be used to
monitor the rate of kidney volume enlargement in ADPKD.8
To identify rapidly the potential therapeutic benefit of a
future treatment, it is necessary to establish standardized
imaging techniques and volumetric methods, which reliably
detect kidney volume changes within a short time interval.
We have prospectively evaluated 100 young ADPKD
patients with preserved renal function by two serial MRI
volume determinations within an interval of 6 months.
We hypothesized that a manual segmentation volumetry
method applied to MRI scans which were obtained with
an optimized T1-weighted acquisition protocol without
administration of gadolinium-based MR contrast agents
would be accurate and reliable to assess kidney volume
change within 6 months.
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RESULTS
Patient characteristics
A total of 100 Caucasian ADPKD patients were studied. A
total of 97 patients had a positive family history for ADPKD.
The demographic and clinical data of all patients are
summarized in Table 1. The diagnosis of ADPKD was
established in 89 patients before study inclusion at the age of
23.3±7.9 years. Twenty-five percent of these patients had
ADPKD-related symptoms at the time of diagnosis. In 11
patients, the diagnosis of ADPKD was established at screen-
ing for study inclusion. At study inclusion, 47 patients
reported ADPKD-related symptoms, including recurrent
flank pain, episodes of macrohematuria, and cyst infections.
During follow up, 74 patients were asymptomatic, 25
experienced flank pain, 3 macrohematuria, and 1 patient
had a cyst infection. Two-thirds of the patients had
hypertension, mostly treated with angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers. The
baseline estimated creatinine clearance amounted to
109.8±25.5 ml/min (98.2±18.5 ml/min/1.73 m2) and the
urinary albumin/creatinine ratio was 3.86±8.74 mg/mmol;
both parameters remained unchanged during the 6-month
follow up (108.4±24.7 ml/min and 3.08±3.59 mg/mmol at
month 6; P¼ 0.259 and 0.497, respectively). Microalbumi-
nuria was present in 25 patients and only 2 patients had
macroalbuminuria.
Kidney and cyst volume changes within 6 months
MRI volumetry-based volumes of both kidneys of all 100
ADPKD patients were assessed twice within 192±15 days.
Figure 1a displays the total kidney volume (TKV) at baseline
and at month 6 in all patients as a function of their age. The
mean TKV amounted to 1003±568 cm3 at baseline and
increased significantly to 1034±602 cm3 (Po0.001). The
mean TKV change was 31.8±72.0 cm3 (2.71±4.82%). This
measured kidney volume increase in 6 months corresponded
to an extrapolated value of 62.2±136.5 cm3 (5.36±9.47%)
per year.
Figure 1b shows that TKV increased in most patients but
decreased in some. A significant decrease of the renal volume
(i.e. outside the 95% confidence interval (CI) for the volume
measurements) was found in 13 single kidneys of 10 patients.
Their MR images were reviewed in detail. In six patients
(seven single kidneys), the volume decrease could be
attributed to the rupture of one or few large cysts. These
six patients were all male, had significantly higher TKV
(1445±435 vs 982±568 cm3; P¼ 0.034) and reported more
symptoms at baseline (recurrent flank pain in 100 vs 32%,
episodes of macrohematuria in 83 vs 16%, cyst or urinary
tract infections in 33 vs 12%, and hypertension in 100 vs
65%), whereas the age was similar compared with the
remainder of the cohort (33.4±7.6 vs 31.1±6.4 years;
P¼ 0.384). Only two of these six patients reported flank pain
and none had macrohematuria during follow up. Figure 2
shows an example for the rupture of a large cyst at the lower
pole of the left kidney between baseline and follow-up.
The mean left kidney volume was higher than the right
(530±301 vs 480±284 cm3; Po0.001), whereas the growth
rate did not differ significantly (2.50±5.48 vs 2.80±5.14%;
P¼ 0.509). Figure 3a shows that the baseline volumes of the
Table 1 | Demographic and clinical data at baseline in 100
ADPKD patients
Demographic characteristics
Age (years) 31.2±6.4
Sex (female; male) 37; 63
Family history of ADPKD 97
BMI (kg/m2) 24.3±3.8
SBP/DBD (mm Hg) 133.9±16.5/84.8±10.6
Current smoker 36
Symptoms and complications of ADPKD
Hypertension 67
Antihypertensive treatment 41
ACEI and/or ARB therapy 39
Recurrent flank pain 36
History of macrohematuria 20
History of cyst infections 13
History of intracranial bleeding 2
Renal parameters
Serum creatinine (mmol/l) 90.2±19.1
Estimated creatinine clearance (C–G; ml/min) 109.8±25.5
ACEI, angiotensin-converting enzyme inhibitor; ADPKD, autosomal-dominant
polycystic kidney disease; ARB, angiotensin receptor blocker; BMI, body mass index;
C–G, Cockcroft–Gault; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Data represent mean (s.d.) or the number of patients.
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Figure 1 | Total kidney volume progression within 6 months.
(a) Total kidney volume (TKV) in relation to age in 100 individual
ADPKD patients (female in red, male in blue). (b) TKV change
(DTKV) of individual patients lined up in ascending order.
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right and left kidney were highly correlated in individual
patients (r¼ 0.905, Po0.001). Furthermore, Figure 3b
reveals that their growth rates were also correlated
(r¼ 0.702, Po0.001). When six patients with documented
cyst rupture were excluded, the correlation of the growth
rates of the right and left kidney increased (r¼ 0.818,
Po0.001).
Using T2-weighted MRI volumetry, we also determined
total cyst volume. Total cyst volume was 476±440 cm3 at
baseline and increased by 32.8±92.5 cm3 (5.45±14.28%) to
509±490 cm3 (Po0.001). The change in total cyst volume
was directly correlated with the change in TKV (r¼ 0.780,
Po0.001). The mean noncystic renal volume (i.e. TKV
minus total cystic volume) at baseline was 527±183 cm3 and
did not change during follow up (526±187 cm3, P¼ 0.867).
To assess the association between growth rate and kidney
volume, the patients were stratified into three subgroups
according to their kidney volume and the volume subgroups
were further stratified by age (Table 2). Six patients who
exhibited a significant volume loss due to a cyst rupture and
two patients with unilateral renal agenesis were excluded
from this analysis. The proportion of young patients declines
with increasing TKV, reflecting that TKV increased with age.
There was a positive correlation between TKV and TKV
change in both age subgroups (r¼ 0.588, Po0.001 and
r¼ 0.612, Po0.001 for ageo30 and 430 years, respectively)
and in the subgroups of higher age also the percentage TKV
change correlated with TKV (r¼ 0.080, P¼ 0.639 for age
o30 years and r¼ 0.485, Po0.001 for age 430 years). The
TKV change was inversely correlated with age in most TKV
subgroups. For the correlation of absolute and percentage
TKV change with age, the coefficients are r¼0.379,
P¼ 0.013 and r¼0.418, P¼ 0.006 in patients with TKV
750 ml; r¼0.308, P¼ 0.076 and r¼0.360, P¼ 0.036 in
patients with TKV 750–1500 ml; r¼0.143, P¼ 0.597 and
r¼0.165, P¼ 0.541 in patients with TKV41500 ml. The
percentage but not absolute kidney volume progression was
also inversely correlated with age in the whole cohort
(r¼0.242, P¼ 0.020 and r¼ 0.015, P¼ 0.891, respectively).
Reproducibility of MRI kidney volumetry
The comparison of single kidney volume (SKV) measure-
ments for observer 1 (D.P.) and 2 (F.K.) are shown as Lin’s
concordance correlation plot in Figure 4. The concordance
correlation coefficients (95% CI) were 1.000 (0.999–1.000)
for intraobserver and 0.996 (0.995–0.999) for interobserver
correlations, representing excellent agreement. The coeffi-
cient increases in value as a function of the nearness of the
data to the line of perfect concordance (accuracy) and the
tightness of the data around this axis (precision). Accuracy
and precision was high over the entire range of measured
kidney volumes, indicating that there is similar reliability in
measuring lower and higher SKV.
Table 3 shows the measurement error, expressed as the
within-subject standard deviation (sw) for intraobserver and
interobserver duplicate measurements. The measurement
error was similar over the entire range of kidney volumes
(t¼ 0.139, P¼ 0.163 and t¼ 0.142, P¼ 0.155 for intra-
observer and interobserver measurement error, respectively).
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Figure 3 | Comparison between left and right kidney volumes
and their changes. (a) A high correlation was found between left
and right kidney volumes at baseline (r¼ 0.905, Po0.001) and (b)
between single kidney volume changes (DSKV) of the left and
right kidney over 6 months in 100 patients (r¼ 0.702, Po0.001).
The correlation between DSKV of the right and left kidney increased
after the exclusion of patients with documented cyst rupture
(r¼ 0.818, Po0.001). Squares represent individual patients, stars
represent patients with documented cyst rupture (n¼ 6). Lines of
linear regression with 95% confidence interval are shown.
**
Figure 2 | Coronal T2-weighted MRI sections reveal the
rupture of a large cyst. (a) At month 0, a large cyst (**) at the
lower pole of the left kidney is seen. (b) The large lower left pole
cyst has disappeared at month 6. In the 6-month observation
period, the right kidney volume increased by 44 cm3 whereas the
left kidney volume decreased by 59 cm3 and hence total kidney
volume was reduced by 15 cm3 within 6 months.
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The difference between an observer’s measurement and the
true kidney volume would be expected to be less than 1.96sw
for 95% of measurements. Thus, the 95% CI for SKV
measurements as calculated based on the interobserver sw is
±15.687 cm3 and therefore lower than the mean positive or
negative SKV change of ±25.3 cm3 during follow up.
For single kidney cyst volume measurements, the
concordance correlation coefficients and the within subjects
standard deviations for duplicate measurements (sw) are
shown in Table 3.
Correlation between renal volume and clinical variables
Male patients had larger renal volumes than female patients
(TKV 1158±555 vs 738±493 cm3; Po0.001). TKV was also
higher in patients with arterial hypertension compared with
normotensives (1190±581 vs 622±277 cm3; Po0.001) and
in patients who reported previous episodes of hematuria
(1399±581 vs 904±522 cm3; Po0.001) and it was positively
associated with albuminuria (r¼ 0.424, Po0.001) and
negatively associated with creatinine clearance (r¼0.348,
Po0.001). These associations remained significant after
normalization of TKV for body surface area and adjustment
for age (for the association of TKV with gender P¼ 0.004,
hypertension Po0.001, hematuria Po0.001, creatinine
clearance P¼ 0.002, and albuminuria Po0.001).
To identify risk factors for accelerated progression, the
percentage kidney volume change was correlated with clinical
and demographical variables. Patients with documented cyst
rupture or unilateral renal agenesis were excluded from this
analysis. Male patients tended to have higher growth rates
than female patients, but this difference was not statistically
significant (3.24±5.07 vs 2.25±4.43%, P¼ 0.339). Albumi-
nuria was positively associated with volume growth rate
(r¼ 0.298, P¼ 0.005). This association remained significant
after adjusting for sex, age, diagnosis of hypertension, use of
angiotensin converting enzyme inhibitor/angiotensin recep-
tor blockers, systolic blood pressure, creatinine clearance,
TKV at baseline, and the interval between the two MRI
acquisitions (P¼ 0.041).
Table 2 | Relationship between age, total kidney volume, volume progression, and creatinine clearance
Total kidney volume Estimated creatinine clearance
Total kidney volume and age group N At baseline (ml) Change (ml) Change (%) At baseline (ml/min) Change (ml/min)
o750 ml and o30 years 23 544±126 18.5±24.8 2.79±4.81 120±27 0.9±15.1
o750 ml and X30 years 18 530±149 1.2±17.0 0.06±4.06 100±22 0.4±10.1
750–1500 ml and o30 years 11 1016±198 39.2±24.6 4.60±2.60 126±26 2.6±8.7
750–1500 ml and X30 years 23 1054±156 24.9±46.0 2.52±4.31 109±26 2.7±14.1
41500 ml and o30 years 2 1857±261 112.6±38.1 6.16±1.30 116±2 13.3±21.3a
41500 ml and X30 years 14 2043±386 123.7±118.2 5.94±4.06 100±16 3.2±9.4
Data represent mean (s.d.).
aThe apparent improvement of creatinine clearance is due to a 15 kg weight gain during follow up of one of these two patients affecting the estimate of creatinine clearance
according to the Cockcroft–Gault formula.
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Figure 4 | Intraobserver and interobserver agreement of
kidney volume measurements. Lin’s concordance correlation
plots demonstrating high degree of agreement between repeated
measurements of observer 1 (n¼ 48; a) and between
measurements of observers 1 and 2 (n¼ 48; b). All measurements
are in cm3. SKV, single kidney volume.
Table 3 | Intraobserver and interobserver agreement of
kidney volumetry measurements
Comparison N=48
Lin’s concordance
correlation coefficient,
qc (95% CI)
Within-subject standard
deviation, sw (cm
3)
Kidney volume
Observer 1 vs 1 1.000 (0.999–1.000) 6.130
Po0.001
Observer 1 vs 2 0.996 (0.995–0.999) 8.003
Po0.001
Cyst volume
Observer 1 vs 1 0.993 (0.989–0.997) 9.8387
Po0.001
Observer 1 vs 2 0.943 (0.918–0.969) 25.500
Po0.001
Comparison of single kidney volume and cyst volume of single kidney measure-
ments by two observers.
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DISCUSSION
The results of the present study demonstrate that an
unenhanced MRI technique combined with manual segmen-
tation volumetry can provide reproducible measures of renal
volumes useful for monitoring changes that occur in early
ADPKD within a short time interval.
Various imaging modalities have been used to monitor
volume progression in ADPKD, including sonography,9
MRI8, and computed tomography.10–13 Sonography is highly
operator dependent and lacks accuracy to detect small
changes in renal volume.14 For safety reasons, MRI is
favorable compared with computed tomography technique,
as it avoids the radiation exposure and administration of
iodinated contrast media. Previously, gadolinium-enhanced
MRI has been used for renal volume determination in
ADPKD patients.8 We used unenhanced MR image sequences
only because gadolinium-based MR contrast agents have
been associated with nephrogenic systemic fibrosis in patients
with renal disease.15,16 Although nephrogenic systemic
fibrosis occurred predominantly in patients with glomerular
filtration rate o60 ml/min, the avoidance of gadolinium-
based MR contrast agents is desirable for further studies in
patients with ADPKD and impaired kidney function. As the
US Food and Drug Administration (FDA) has raised
concerns over using gadolinium in ADPKD patients, also
the Consortium of Radiologic Imaging Studies of Polycystic
Kidney Disease (CRISP) has migrated to an unenhanced MRI
protocol for further studies.
Volume determination from MRI data requires a segmen-
tation of MR images. An automated method would be
desirable but is not easily applicable to polycystic kidneys
because of their inhomogeneous structure. Semiautomated
segmentation methods include region-based thresholding
and stereology. In region-based thresholding, an intensity
threshold is set by a trained analyst for every image slice to
differentiate the area of interest from surrounding tissue. This
method is limited by the intrinsic spatial intensity fluctuation
of MR images. The human visual system has the ability to
overcome spatial intensity fluctuations and resolve small
contrast differences and is probably most feasible for MR
image segmentation. The stereological technique depends on
the capability of an analyst to differentiate adjacent tissues
and makes use of a grid superimposed on the image data,
which facilitates volume determination but does not utilize
the full resolution of image data.17,18 We used a manual
contour tracing method, which is more time consuming than
semiautomated approaches but allows a very precise defini-
tion of organ boundaries utilizing the full resolution of MR
data. Manual segmentation is not applicable to cyst volume
determination due to the large number of cysts. Thus, we
used a region-based thresholding method to determine cyst
volumes.
The question, if renal volume changes can be measured
within a 6-month interval, depends on the magnitude of the
measurement imprecision compared with the actual kidney
volume change. The accuracy and reliability of renal volume
measurements was mirrored by excellent concordance among
all measurements as continuous variables, based on Lin’s
concordance correlation coefficients of 1.000 and 0.996 for
intra- and interobserver correlations. The 95% CI for kidney
volume measurements as calculated based on the inter-
observer variability was considerably lower than the true
volume change. This applies for the entire range of measured
kidney volumes as the measurement error was independent
of the kidney volume. The high accuracy and reproducibility
of our method thus allows monitoring changes that occur in
early ADPKD within a short time interval. Cyst volume
measurements were also reliable but the measurement error
was larger compared with kidney volume measurements
owing to the use of a region-based thresholding method
instead of manual segmentation.
The CRISP analyzed annual contrast-enhanced MRI over
3 years in 241 American ADPKD patients.8 The renal volume
was measured in T1-weighted gadolinium-enhanced images
with the use of a stereologic method. At baseline, TKV
amounted to 1076 cm3 and increased by 63.4 cm3 or 5.27%
per year. Using a manual segmentation technique, we studied
100 European ADPKD patients with similar baseline
characteristics as the CRISP cohort. TKV increased by
31.8 cm3 within 6 months corresponding to a growth rate
of 2.71%. Assuming an exponential growth kinetic with a
constant growth rate, the calculated annual growth rate was
5.36% in our cohort and hence very similar to the CRISP
results. In further analogy to the CRISP data, we could
confirm the high degree of correlation between right and
left renal volumes and their growth rates. Thus, we were able
to confirm the CRISP results in an European ADPKD
population.
In seven kidneys, we identified the asymptomatic
spontaneous rupture of large cysts, causing a significant
reduction of the kidney volume. Cyst loss has been judged
not to contribute appreciably to the renal growth kinetic over
the long term.19 In the short term however, we could
demonstrate that cyst ruptures can cause considerable
reduction of renal volume. Thus, if volumetry data are used
to monitor disease progression over a short time interval,
complemented detailed image analysis can be helpful.
The kidney volume enlargement in ADPKD has been
suggested to follow an exponential characteristic with a
growth rate that is patient-specific and relatively constant
over time.19 On the basis of two measurements per patient,
the growth characteristic cannot be defined exactly. However,
the correlation between TKV and TKV growth found in both
age subgroups of our cohort supports the hypothesis of a
patient-specific growth rate. The percentage TKV change
correlated with TKV only in patients 430 years and the
correlation between TKV and TKV growth gained strength
with increasing patient age. It is clear that the enlargement of
the polycystic kidney is due to the growth of the cysts. With
increasing age, cyst volume contributes proportionally more
and more to TKV. Hence, the rate of cyst growth will
influence total renal volume more pronouncedly in advanced
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disease. As a consequence, TKV in relation to age might serve
as a prognostic marker in patients 430 years but it seems to
be less reliable in young patients.
We found the percentage renal volume growth rate to be
higher in young patients. Rather than reflecting an
accelerated progression in these patients, this finding might
be due to selection bias: young patients with mild disease
were probably underrepresented in our cohort because the
diagnosis was not yet established or they were not motivated
for study participation by lack of symptoms.
Renal volume in ADPKD has previously been correlated
with other markers of advanced disease, such as hyper-
tension, albuminuria, and reduced glomerular filtration
rate.20,21 Previously identified risk factors for accelerated
disease include male sex, gross hematuria, early onset of
hypertension, and proteinuria.9,21–23 Our results are in line
with these previous studies as TKV at baseline was positively
correlated with hypertension, hematuria, and albuminuria
and albuminuria was associated with accelerated volume
progression.
Taken together, the high reproducibility and accuracy of
the measurements, the correlation of the volumetry results
with clinically known progression markers and the accor-
dance of our results with the CRISP data underscore the
validity of our method to monitor changes in early ADPKD
within an interval of 6 months. The method we describe here
can be easily implemented into clinical practice as we relied
on a standardized MRI acquisition protocol and commer-
cially available US Food and Drug Administration-approved
volumetry software. These data may have implications for
designing future interventional trials and are important for
examining the therapeutic benefit of ongoing clinical trials
for this devastating disease.
MATERIALS AND METHODS
Patient population
The subjects for this study were 100 participants of an ADPKD
registry. The diagnosis of ADPKD was based on ultrasonographic
diagnostic criteria in patients with a family history of ADPKD.24 In
patients with a negative family history, proof of a disease-causing
mutation in the PKD1 gene was obtained by genetic testing
(sequencing analysis by Athena Diagnostics Inc., Worcester, MA,
USA). As we also aimed to screen patients for a clinical trial, they
generally fulfilled the inclusion criteria of that trial,25 most
importantly age 18–40 years and estimated creatinine clearance
X70 ml/min. Patients were studied at the University Hospital of
Zu¨rich, Switzerland, between April 2005 and March 2008. The study
was conducted according to the guidelines on Good Clinical Practice
and the Declaration of Helsinki Principles. Study approval was
obtained from the local ethics committee, and all patients gave
written, informed consent.
Clinical evaluation and laboratory analyses
After screening and enrolment, a detailed medical history was
obtained, including ADPKD-related symptoms, previous hospitali-
zation, and medication. Blood pressures were measured twice in
each arm at every study visit in sitting position after a rest of 5 min,
using an oscillometric blood pressure monitor (Boso-Medicus,
Jungingen, Germany). The lower of the two consecutive measure-
ments in the arm with the higher blood pressure was used
for analysis. Arterial hypertension was defined as systolic blood
pressure X140 mm Hg or diastolic blood pressure X90 mm Hg at
all three study visits (screening, baseline and month 6), or treatment
with an antihypertensive drug. Blood samples were obtained
at month 0 and 6 for the determination of serum creatinine
(IDMS traceable modified Jaffe´ method). Creatinine clearance
was estimated according to the Cockcroft–Gault formula. The spot
urine was analyzed for the ratio of albumin to creatinine
(mg/mmol).
Magnetic resonance imaging
All subjects underwent a standardized MRI protocol at month 0 and
6 using an 1.5 T scanner (Signa EchoSpeed EXCITE HD or HDx; GE
Healthcare, Waukesha, WI, USA), as described elsewhere.25 Briefly,
for signal reception in all examinations, an eight-channel ante-
roposterior-phased array surface coil was placed around the patient
covering the entire kidneys. The imaging protocol included
unenhanced sequences only. After obtaining a localizer sequence, a
coronal single shot fast spin echo sequence (TR ms/TE ms 1349/90.1;
field of view, 48 48 cm; acquisition matrix, 384 224; section
thickness, 4 mm; no interslice gap) was acquired in breathhold
technique to obtain an overview of the extent of the cystic disease of
the patient. On the basis of this coronal sequence, the transaxial
sequences were planned. The transaxial sequences consisted of two
breathhold T1-weighted fast-spoiled gradient echo sequences
(TR ms/TE ms¼ 85/1.4, flip angle, 701) with 3 and 4 mm slice
thicknesses and no interslice gap. Sequences with 4 mm slice
thickness were only assessed if 3 mm sequences were not analyzable
due to artefacts or insufficient coverage of the volume of interest. In
addition, a transaxial T2-weighted fast spin echo sequence with
respiratory triggering was performed (TR ms/TE ms¼ 17,143/102.8)
with 3 mm slice thickness and no interslice gap.
Renal volume measurements
Kidney volumes were measured by manually tracing the kidney
contours using volume analysis software implemented on an
Advantage Windows workstation (4.4, GE Healthcare, Buc, France).
The renal volume was calculated for each kidney by multiplying all
outlined areas by the section thickness and summing the volume of
each section. Non-kidney parenchyma, for example renal hilus, was
identified by checking adjacent slides if needed and excluded from
the measurement. For measurements of the TKVs, the T1-weighted
fast-spoiled gradient echo sequences were used.
For the determination of cyst volumes, a region-based thresh-
olding technique was applied to the axial T2-weighted fast spin echo
sequences. In this sequence, the cysts appear brighter than the renal
parenchyma. An intensity threshold was selected on every image
slice by an analyst. The volume of all cysts was calculated for each
kidney by multiplying cyst areas by the section thickness and
summing the volume of each section. These measurements were also
performed using the Advantage Windows workstation.
Individual kidneys were measured in cm3 and the values
of the right and left kidney were added to calculate the TKV and
the total cyst volume for each patient. The annual change in kidney
volume was determined for each patient assuming an exponential
growth.19
The measurements of total kidney and cyst volumes were
performed by two observers (D.P. and F.K.), which have been trained
by a radiologist and have performed their first measurements under
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supervision. Depending on the kidney size, analysis time was
15–45 min for one single kidney volume determination, whereas cyst
volume measurement required 10–25 min per kidney. For the
assessment of the intraobserver agreement of kidney volume
determination, one of the observers (D.P.) repeated 48 SKV
measurements at a different occasion. To further validate the
measurements, a second independent observer (F.K.) repeated the
measurements and interobserver agreement was determined.
Repeated measurements were performed without knowledge of the
results of earlier measurements or each other’s results.
Statistical analysis
Results are expressed as means±s.d. Means of continuous data were
compared by Student’s t-test. All P-values were two sided for the
comparison with the baseline values, and those less than 0.05 were
considered statistically significant. The Pearson correlation coeffi-
cient was used to test for associations between continuous variables.
TKV and albumin/creatinine ratio variables were log-transformed to
achieve a normal distribution for parametric tests. Multivariate
linear regression was used to determine independent predictors of
growth rate and to adjust TKV for age in the comparison among
patients with different clinical characteristics.
Intra- and interobserver agreement of the kidney volumetry was
evaluated by computing Lin’s concordance correlation coefficient
(rc) for each comparison.
26 In addition, the within-subject standard
deviation was calculated to assess the reproducibility of kidney and
cyst volume measurement.27 The Kendall t rank correlation
coefficient between the standard deviation and the mean of replicate
measurements was used to test whether the measurement error was
proportional to the volume measured.
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